Stocktoria
ARVINAS, INC. ARVN
ARVINAS, INC. (ARVN) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $262.6M at a -30.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.778 |
| Retained earnings / assets | -2.246 |
| EBIT / assets | -0.165 |
| Equity / liabilities | 1.528 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ARVN | ARVINAS, INC. | 4/9 | -1.73 | — | -0.3% |
| LGND | LIGAND PHARMACEUTICALS INC | 4/9 | 6.75 | 48.9 | +60.4% |
| SDGR | Schrodinger, Inc. | 4/9 | -0.33 | — | +23.3% |
| HROW | HARROW, INC. | 6/9 | 1.29 | — | +36.4% |
| RCUS | Arcus Biosciences, Inc. | — | -0.75 | — | -4.3% |
| KROS | Keros Therapeutics, Inc. | 6/9 | 11.55 | 2.5 | — |
| AUPH | Aurinia Pharmaceuticals Inc. | 5/9 | 5.18 | 7.7 | +20.4% |
About ARVINAS, INC.
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
FAQ
Is ARVN financially healthy?
ARVINAS, INC.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does ARVN pay a dividend?
No, ARVINAS, INC. does not currently pay a dividend.
How profitable is ARVN?
In FY2025, ARVINAS, INC. had a net margin of -30.8% and a return on equity of -18.6%.
What is the analyst price target for ARVN?
The average Wall-Street price target for ARVINAS, INC. is $14.80, about 66.9% above the recent price, from 15 analysts (consensus: buy).
Is ARVN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ARVINAS, INC.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.